News | March 09, 2021
Vivimed Labs receives products approvals from Uzbekistan
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
The transition of the existing Anemia Mukt Bharat programme into Anemia Mukt Bharat Abhiyaan signals a shift towards a more comprehensive, technology-enabled and community-driven approach
The study also met its key secondary endpoint for bone health
Subscribe To Our Newsletter & Stay Updated
